Inhibition of P-glycoprotein transport activity in a resistant mouse lymphoma cell line by diterpenic lactones

被引:0
|
作者
Ferreira, MJU
Gyémánt, N
Madureira, AM
Molnár, J
机构
[1] Univ Lisbon, Ctr Estudos Ciencias Farmaceut, Fac Farm, P-1600083 Lisbon, Portugal
[2] Univ Szeged, Dept Med Microbiol & Immunobiol, H-6720 Szeged, Hungary
关键词
diterpenes; helioscopinolides; Euphorbia; multidrug resistance;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Multidrug resistance (MDR) is believed to be a major reason for the failure of cancer treatment. It is in most cases caused by the activity of the various ABC transporters, multidrug resistance (MDR) gene-encoded p-glycoproteins that pump anticancer drugs out of the cells. P-glycoprotein (P-gp) and multidrug resistance-associated protein (MRP1) are the most important and widely studied members of the ABC superfamily of transporters. The ability of four diterpenic lactones isolated from Euphorbia species to modulate the transport activity of P-gp in mouse lymphoma cells was evaluated by flow cytometry. The reversion of MDR was investigated by using a standard functional assay with rhodamine 123 as a fluorescent substrate analogue of doxorubicin. Verapamil was applied as a positive control. All the compounds were able to reverse the MDR of the tested human MDR] gene-transfected mouse lymphoma cells, in a concentration-dependent manner from 4 to 40 mu g/mL, in a short-term experiment below the cytotoxic doses.
引用
收藏
页码:3259 / 3262
页数:4
相关论文
共 50 条
  • [21] Novel tetramethylpiperidine-substituted phenazines are potent inhibitors of P-glycoprotein activity in a multidrug resistant cancer cell line
    VanRensburg, CEJ
    Anderson, R
    Joone, G
    Myer, MS
    OSullivan, JF
    ANTI-CANCER DRUGS, 1997, 8 (07) : 708 - 713
  • [22] Inhibition of P-glycoprotein transport function by N-acylphenothiazines
    Wesolowska, O
    Molnár, J
    Motohashi, N
    Michalak, K
    ANTICANCER RESEARCH, 2002, 22 (05) : 2863 - 2867
  • [23] Detection or P-glycoprotein activity in cell lines and resistant leukemia using Idarubicin and Daunorubicin
    Bellio, L
    Pagnucco, G
    Buonanno, MC
    Vanelli, L
    Maiocchi, MA
    Lazzarino, M
    Bernasconi, C
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 1316 - 1316
  • [24] GLYCOSYLATION OF P-GLYCOPROTEIN IN A MULTIDRUG-RESISTANT KB-CELL LINE, AND IN THE HUMAN TISSUES
    ICHIKAWA, M
    YOSHIMURA, A
    FURUKAWA, T
    SUMIZAWA, T
    NAKAZIMA, Y
    AKIYAMA, S
    BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1073 (02) : 309 - 315
  • [25] Resistance to Paclitaxel in a Cisplatin-Resistant Ovarian Cancer Cell Line Is Mediated by P-Glycoprotein
    Stordal, Britta
    Hamon, Marion
    McEneaney, Victoria
    Roche, Sandra
    Gillet, Jean-Pierre
    O'Leary, John J.
    Gottesman, Michael
    Clynes, Martin
    PLOS ONE, 2012, 7 (07):
  • [26] Changes in P-glycoprotein activity are mediated by the growth of a tumour cell line as multicellular spheroids
    Ponce de León Valeria
    Barrera-Rodríguez Raúl
    Cancer Cell International, 5
  • [27] Changes in P-glycoprotein activity are mediated by the growth of a tumour cell line as multicellular spheroids
    de Leon Valeria, Ponce
    Raul, Barrera-Rodriguez
    CANCER CELL INTERNATIONAL, 2005, 5 (1)
  • [28] Inhibition Mechanism of P-glycoprotein Mediated Efflux by mPEG-PLA and Influence of PLA Chain Length on P-glycoprotein Inhibition Activity
    Li, Wenjing
    Li, Xinru
    Gao, Yajie
    Zhou, Yanxia
    Ma, Shujin
    Zhao, Yong
    Li, Jinwen
    Liu, Yan
    Wang, Xinglin
    Yin, Dongdong
    MOLECULAR PHARMACEUTICS, 2014, 11 (01) : 71 - 80
  • [29] The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells
    Holland, ML
    Panetta, JA
    Hoskins, JM
    Bebawy, M
    Roufogalis, BD
    Allen, JD
    Arnold, JC
    BIOCHEMICAL PHARMACOLOGY, 2006, 71 (08) : 1146 - 1154
  • [30] Inhibition of P-glycoprotein activity in human leukemic cells by mifepristone
    Fardel, O
    Courtois, A
    Drenou, B
    Lamy, T
    Lecureur, V
    lePrise, PY
    Fauchet, R
    ANTI-CANCER DRUGS, 1996, 7 (06) : 671 - 677